Sensei Biotherapeutics Statistics
Total Valuation
SNSE has a market cap or net worth of $35.40 million. The enterprise value is $14.83 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SNSE has 1.26 million shares outstanding. The number of shares has increased by 0.52% in one year.
| Current Share Class | 1.27M |
| Shares Outstanding | 1.26M |
| Shares Change (YoY) | +0.52% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.21% |
| Owned by Institutions (%) | 6.74% |
| Float | 736,022 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.81, with a Debt / Equity ratio of 0.09.
| Current Ratio | 5.81 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -520.74 |
Financial Efficiency
Return on equity (ROE) is -70.18% and return on invested capital (ROIC) is -39.78%.
| Return on Equity (ROE) | -70.18% |
| Return on Assets (ROA) | -37.04% |
| Return on Invested Capital (ROIC) | -39.78% |
| Return on Capital Employed (ROCE) | -103.46% |
| Weighted Average Cost of Capital (WACC) | 3.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +214.51% in the last 52 weeks. The beta is -0.08, so SNSE's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | +214.51% |
| 50-Day Moving Average | 20.98 |
| 200-Day Moving Average | 11.95 |
| Relative Strength Index (RSI) | 52.79 |
| Average Volume (20 Days) | 112,414 |
Short Selling Information
The latest short interest is 715,845, so 56.74% of the outstanding shares have been sold short.
| Short Interest | 715,845 |
| Short Previous Month | 538,588 |
| Short % of Shares Out | 56.74% |
| Short % of Float | 97.26% |
| Short Ratio (days to cover) | 0.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.95M |
| Pretax Income | -24.14M |
| Net Income | -24.14M |
| EBITDA | -23.52M |
| EBIT | -23.95M |
| Earnings Per Share (EPS) | -$19.16 |
Full Income StatementBalance Sheet
The company has $25.04 million in cash and $2.02 million in debt, with a net cash position of $23.02 million or $18.25 per share.
| Cash & Cash Equivalents | 25.04M |
| Total Debt | 2.02M |
| Net Cash | 23.02M |
| Net Cash Per Share | $18.25 |
| Equity (Book Value) | 23.01M |
| Book Value Per Share | 18.24 |
| Working Capital | 21.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.38 million and capital expenditures -$16,000, giving a free cash flow of -$22.40 million.
| Operating Cash Flow | -22.38M |
| Capital Expenditures | -16,000 |
| Depreciation & Amortization | 436,000 |
| Net Borrowing | -884,000 |
| Free Cash Flow | -22.40M |
| FCF Per Share | -$17.75 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SNSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.52% |
| Shareholder Yield | -0.52% |
| Earnings Yield | -63.77% |
| FCF Yield | -59.17% |
Analyst Forecast
The average price target for SNSE is $72.50, which is 158.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $72.50 |
| Price Target Difference | 158.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
